Skip to content
    GDRX
    Earnings call· Jun 2026(Q2 FY26)

    GoodRx Holdings Q2 FY26 earnings call GDRX

    Aug 6, 2026 Source

    Executive summary

    GoodRx Q2 FY26 — Strong Pharma Direct and Subscription Growth Drive Raised Outlook

    GoodRx delivered a strong Q2 FY26, exceeding revenue expectations and raising its full-year outlook, driven by robust performance in Pharma Direct and subscriptions. The company is actively transitioning its business model towards these higher-value offerings, which is expected to lead to more durable growth, despite a planned moderation in prescription transaction revenue and monthly active consumers. Management is focused on consistent execution of growth initiatives and leveraging AI for operational efficiency.

    Highlights

    5

    • Revenue exceeded expectations, reaching $200.4 million.

    • Pharma Direct revenue grew 76% year-over-year and 18% quarter-over-quarter.

    • Subscription revenue increased 39% year-over-year to $28.5 million.

    • Full-year revenue guidance raised to a range of $790 million to $805 million, implying a return to year-over-year growth earlier than anticipated.

    • Adjusted EBITDA guidance raised to a range of $240 million to $250 million.

    Concerns

    3

    • Monthly active consumers (MACs) totaled 5 million, down 12% year-over-year and sequentially.

    • Prescription transactions revenue was $106.4 million, in line with outlook but reflecting sequential moderation.

    • Chief Financial Officer transition with Chris McGinnis departing and Justin Fengler appointed.

    Guidance & targets

    3
    CategoryTargetConfidence
    Full-year revenue
    $790 million to $805 million
    high materiality
    High
    Full-year adjusted EBITDA
    $240 million to $250 million
    high materiality
    High
    Full-year Pharma Direct revenue growth
    more than 70%
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Prescription Transactions Revenue
    Revenue was in line with previously provided outlook, reflecting normal seasonality in integrated savings program and a deliberate shift of investment towards new subscription offerings. Monthly active consumers declined sequentially.
    Monthly active consumers: 5 millionMonthly active consumers growth: down 12% year-over-year
    		$106.4 million———
    Pharma Direct
    Growth driven by continued momentum in GLP-1 access programs and strong execution across non-GLP-1 business. The company continues to deepen manufacturer partnerships and expand its consumer direct pricing platform.
    		$61.6 million76%18%—
    Subscription
    Driven by ongoing demand for condition-specific offerings, particularly weight loss, and benefiting from the launch of GoodRx Companion in May. Subscriptions are becoming a central part of how the company serves and retains consumers.
    Number of subscription plans growth: 14% year-over-year
    		$28.5 million39%——

    Operational metrics

    7
    Monthly active consumers
    5 milliondown 12% year-over-year
    Q2 FY26

    Reflects normal seasonality in integrated savings program and a deliberate shift of product and marketing investment towards new subscription offerings.

    Annual site visits
    over 280 million
    annual

    Across the platform, indicating a large high-intent audience.

    Pharma Direct average deal size
    increased
    year-over-year

    Reflecting expansion of existing partnerships and greater alignment around enterprise scale programs.

    Number of consumer direct pricing programs
    more than 135
    Q2 FY26

    Including additions of top brands like Jardiance, Nurtec, Otezla, and Rapaflo.

    E-commerce capability reach
    nearly 6,000
    Q2 FY26

    Allows consumers to engage digitally before arriving at the pharmacy.

    GLP-1 Medicare bridge program pricing
    $50
    per prescription

    Offers pricing to eligible Medicare beneficiaries, but includes specific authorization, eligibility, and processing requirements that limit its reach.

    Brand scripts abandoned annually
    over $1 billion
    annual

    Represents a drain on the healthcare system as patients are unable to get prescribed therapies due to cost.

    Industry KPIs

    3
    MetricValueDetails
    Adjusted EBITDA$63.7 millionUSD
    Revenue adjusted EBITDA guidanceRevenue: $790M-$805M; Adjusted EBITDA: $240M-$250MUSD
    Subscription recurring revenue growth39%%

    Product announcements

    1
    ProductTypeDetails
    GoodRx Companionlaunch

    Deals & partnerships

    1
    TrumpRxNationwide pharmacy access for generics

    GoodRx brought its nationwide pharmacy access to TrumpRx as a launch partner for generics, giving consumers more choice in where they fill.

    Risks & headwinds

    5
    Declining Monthly Active Consumers (MACs)Q2 FY26

    5 million, down 12% year-over-year and sequentially

    Mitigation: Strategic shift of product and marketing investment towards new subscription offerings, aiming for higher lifetime value and deeper consumer relationships.

    Moderation in Prescription Transaction RevenueOngoing

    In line with outlook, but expected to moderate over time

    Mitigation: Actively transitioning consumers to subscription offerings, which are expected to generate higher lifetime value and more durable recurring revenue.

    CFO TransitionEffective August 6, 2026

    Chris McGinnis transitioned out, Justin Fengler appointed CFO

    Mitigation: Justin Fengler has been with GoodRx for over 10 years as Chief Strategy and Operations Officer, with deep understanding of the business and financial model.

    Intensifying Affordability Pressures for Consumers and EmployersOngoing, early 2027 rate filings

    ACA marketplace enrollment down nearly 3 million; significant premium increases expected for 2027; employers shifting more expense to employees

    Mitigation: Developing GoodRx Companion as a complement to insurance and Employer Direct to help plan sponsors address prescription affordability in a flexible, targeted way.

    Limitations of GLP-1 Medicare Bridge ProgramJuly 2026 - end of 2027

    $50 pricing on certain GLP-1 therapies, launched July 1, 2026, runs through end of 2027

    Mitigation: Program includes specific authorization, eligibility, and processing requirements that naturally limit its reach; Medicare age consumers represent a modest share of GLP-1 users on the platform today. Expect transparent self-pay access to remain important.

    What to watch in Q3 FY26

    5

    Subscription revenue and plan growth

    next quarter
    CurrentRevenue up 39% YoY; plans up 14% YoY
    TargetContinued strong growth and adoption of GoodRx Companion

    Why it matters

    Subscriptions are a key growth engine and central to the company's strategy for durable recurring revenue and higher lifetime value.

    As we manage kind of the acquisition funnels for that, the retention tactics and things of that nature, it's going to be growth in terms of how well developed that product is. So certainly, the third quarter, fourth quarter, as we go into next year, I think we expect to get sequentially better.

    Q&A highlights

    8

    Given the different business segments and declining MACs, what metrics should investors focus on, and will GoodRx provide new prescription-based metrics to reflect the evolving business model?

    MACs are not a perfect indicator for the evolving business, which is transitioning to subscriptions for higher customer lifetime value. The company is evaluating new KPIs, potentially prescription-based, for future disclosure, likely in 2027, but not this quarter. Pharma Direct's success is driven by a high-intent audience that consistently outperforms other channels.

    “Number of prescriptions, things of that nature are certainly things that we're looking at. And I think that at some point in the future, you would expect us to have something a bit different. It's probably -- it's certainly too early today for us to talk about that.”

    asked by Charles Rhyee · answered by Justin Fengler

    2 min read6 chapters

    Detailed Narrative

    01

    Pharma Direct Momentum and GLP-1 Contribution

    Pharma Direct revenue was a standout in Q2, growing 76% year-over-year and 18% quarter-over-quarter, driven by consumer direct pricing and advertising solutions. The company now boasts over 135 consumer direct pricing programs, including major brands like Jardiance and Nurtec. GLP-1 medications remain a significant driver, with GoodRx supporting several new launches and expansions, and management expects its role in GLP-1 access to remain important as the category evolves, despite the launch of Medicare bridge programs.

    02

    Subscription Growth and GoodRx Companion Launch

    Subscription revenue increased 39% year-over-year to $28.5 million, with the number of subscription plans growing 14% year-over-year. This growth was bolstered by the May launch of GoodRx Companion, a new offering providing 200 free generic medications, hundreds more under $10, and access to affordable online care, dental, vision, labs, and imaging. Companion is now the primary subscription offering, aiming to deliver broader benefits and lower prices across a wider pharmacy network.

    03

    Strategic Shift in Rx Marketplace

    Rx Marketplace performance was in line with expectations, reflecting a sequential moderation and a deliberate shift of product and marketing investment towards subscription offerings. Management views this as a positive evolution, anticipating that transactions historically flowing through Rx Marketplace will increasingly be served by subscriptions. This transition is expected to lead to deeper consumer relationships, higher lifetime value, and increased prescription volume for pharmacies.

    04

    Employer Direct Pipeline Development

    GoodRx is actively developing a significant pipeline for its Employer Direct offering, with initial partners expected to go live in Q4 and Q1. The primary focus is on GLP-1s, combining manufacturer pricing from Pharma Direct with the consumer-facing care model of GoodRx for weight loss. The company also plans to integrate GoodRx Companion, allowing employers to subsidize membership costs and expand access to affordable generic medications for employees.

    05

    Operational Efficiency and AI Integration

    The company is making AI a more intentional part of its operating model to redesign workflows, reduce manual tasks, and accelerate execution. GoodRx is investing in talent and capabilities to embed AI more deeply into platform development, which is expected to enhance product delivery and support greater operating leverage over time⏳.

    06

    Capital Allocation Priorities

    GoodRx's capital allocation priorities remain focused on investing in the business, particularly in high-momentum areas like subscriptions and Pharma Direct. While opportunistic M&A and other capital items are considered, the primary focus is on long-term durable growth. The company did not execute any share buybacks in the last quarter, despite strong free cash flow performance.

    AI-generated summary of the company’s earnings call. Not investment advice.